Targeted therapy in metastatic renal carcinoma.
BACKGROUND
Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma.


METHODS
MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review.


CONCLUSIONS
The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
Jane
J
Mattei
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
Rodrigo Donalisio
RD
da Silva
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
David
D
Sehrt
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
Wilson R
WR
Molina
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States. Electronic address: fernando.kim@dhha.org.
Fernando J
FJ
Kim
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D016503:Drug Delivery Systems; D006801:Humans; D009362:Neoplasm Metastasis; D012074:Remission Induction
Adjuvant treatment; Metastatic disease; Renal cell carcinoma; Renal tumor; Target therapy